Abstract
The widespread popularity of methylxanthine derivatives should be reassessed in light of current evidence. These drugs are relatively weak bronchodilators, respiratory muscle stimulants and inotropic agents and adverse effects, sometimes life threatening, occur fairly frequently. In contrast, beta-2 adrenergic and anticholinergic bronchodilator aerosols used in asthma or chronic obstructive lung disease, and the prophylactic anti-inflammatory aerosols of corticosteroids and cromolyn provide a spectrum of therapeutic choices which address both the inflammatory and bronchoconstrictor components of acute and chronic airflow limitation. Aerosol bronchodilators, in general, are more potent, are virtually free of important side effects, and do not require costly serum level monitoring. Adrenoceptor agonists, together with inhaled steroids, should be considered first-line drugs of choice in managing patients with reversible airflow obstruction associated with asthma or COPD, while methylxanthines should be relegated to the position of third or fourth line drugs, if they are to be used at all. If they are, they should be used with great caution and close patient supervision and, even then, only if benefit, over and above the aerosol br...Continue Reading
References
Feb 16, 1978·The New England Journal of Medicine·J D WolfeM Simmons
Dec 1, 1992·Thorax·M NishimuraY Kawakami
Apr 1, 1988·British Journal of Diseases of the Chest·A G WardmanN J Cooke
Dec 1, 1988·Archives of Internal Medicine·N S Hill
Oct 1, 1988·The American Journal of Medicine·A K RoyR A Levine
Mar 18, 1988·JAMA : the Journal of the American Medical Association·B Littenberg
Mar 1, 1988·The American Review of Respiratory Disease·V R KongraguntaJ T Sharp
Jul 1, 1988·Clinical Pharmacology and Therapeutics·S M SirmansT H Self
Jan 16, 1986·The New England Journal of Medicine·B Littenberg, E H Gluck
Jun 1, 1987·Chest·D L BowtonD A Stump
Sep 1, 1987·Annals of Internal Medicine·K L RiceD E Niewoehner
Jan 1, 1987·The Journal of Allergy and Clinical Immunology·J P JoadM M Weinberger
Mar 17, 1984·Lancet·C T FurukawaC W Bierman
Dec 15, 1984·British Medical Journal·W V Evans
Aug 9, 1984·The New England Journal of Medicine·D MurcianoR Pariente
Sep 25, 1982·British Medical Journal·M D MorganS J Williams
Jan 1, 1982·European Journal of Clinical Pharmacology·J BarclayG J Addis
Nov 1, 1982·Chest·M L EatonD E Niewoehner
Nov 1, 1982·American Heart Journal·R A MatthayB L Zaret
Sep 1, 1981·The American Journal of Medicine·C Shim, M H Williams
Jun 1, 1980·Annals of Internal Medicine·M L EatonD E Niewoehner
Sep 1, 1980·Annals of Internal Medicine·C Shim, M H Williams
Citations
Jun 1, 1993·The American Review of Respiratory Disease·H Milgrom, B Bender
Jul 1, 1993·Chest·K NishimuraT Izumi
Dec 1, 1994·Chest·A IkedaT Izumi
Mar 1, 1995·Chest·K NishimuraT Izumi
Feb 1, 1997·Chest·J L KielyW T McNicholas
Mar 1, 1993·The American Journal of Emergency Medicine·L G YamamotoC M Uechi